Abstract: The present invention forms a mixture basically consisting of threonine, proline, glycine, valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, aspartic acid, serine, glutamic acid, alanine, methionine, histidine and arginine as a unit, by which a body temperature raising effect was observed. The similar body temperature raising effect was observed when carnitine and/or tryptophan is added to the unit. These groups were found to be amino acid mixture-containing agents capable of raising body temperature for food or drink use or medical use. The agents have excellent body temperature raising effect, thereby having the functions of reduction of accumulated body fat, alleviation of excess sensitivity to cold, warming of a cold body, and the like.

Abstract: The invention relates to an anti-HIV agent comprising, as an active ingredient, at least one porphyrin derivative selected from the following derivatives (A) and (B):(A) porphyrins modified with a compound selected from carbodiimides, alkylenediamines and alcohols; and(B) complexes of a plasma protein or a chemically modified plasma protein and a porphyrin which may have been modified with a compound selected from carbodiimides, alkylenediamines and alcohols.This anti-HIV agent is excellent in killing effect on HIV-infected cells, inhibitory effect on cytopathy due to HIV infection and HIV-replication inhibiting effect, and high in safety.

Abstract: Disclosed herein is a novel glycoprotein derived from Ganoderma mycelia. The glycoprotein is free of human hemagglutination ability, and has immunosuppressive activities and a molecular weight of 16,000-18,000 as measured by SDS gel electrophoresis or 12,000-16,000 as measured by tricin-SDS gel electrophoresis. The glycoprotein is produced by culturing Ganoderma mycelia, extracting the resultant Ganoderma mycelia with an aqueous solvent, and then purifying the resultant extract. An immunosuppressive agent containing an effective amount of the glycoprotein is also disclosed.

Abstract: The invention relates to an anti-HIV agent comprising as an effective component a plasma protein of which the polarity of the amino group of the amino acid residue constituting the plasma protein is chemically modified into a negative moiety by a carboxylic acid, for example, by maleic anhydride or succinic anhydride. Plasma proteins modified with dicarboxylic anhydride, which are the effective components of the anti-HIV agent of this invention, inhibit the formation of large cells in mixed culturing of HIV infected cells and non-infected cells as well as the direct infection of helper T cells with HIV.

Abstract: The invention relates to an anti-HIV agent comprising as an effective component a plasma protein of which the polarity of the amino group of the amino acid residue constituting the plasma protein is chemically modified into a negative moiety by a carboxylic acid, for example, by maleic anhydride or succinic anhydride.Plasma proteins modified with dicarboxylic anhydride, which are the effective components of the anti-HIV agent of this invention, inhibit the formation of large cells in mixed culturing of HIV infected cells and non-infected cells as well as the direct infection of helper T cells with HIV. They are very safe compounds and are expected to be applicable to the treatment of HIV infected patients.